Active Studies

Multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of
abatacept to achieve sustained glucocorticoid-free remission in patients with relapsing
non-severe granulomatosis with polyangiitis (Wegener's) (GPA) . Participants will be
randomized 1:1 to receive either abatacept 125 mg or placebo administered by subcutaneous
injection once a week. Participants will continue on study treatment for a minimum of 12
months unless they experience a disease relapse or disease flare.

Participants who experience a non-severe disease relapse, non-severe disease worsening, or
who have not achieved remission by month 6 will have the option of entering an open-label
trial period whereby they would receive open-label abatacept.

The purpose of this study is to determine if intrathecal hydromorphone will relieve pain as
well as intrathecal morphine after cesarean delivery, with fewer side effects.

The purpose of this study is to collect clinical and epidemiological data as well as serum,
plasma, urine, tissue and DNA samples on individuals who have acute liver failure and on
individuals who have acute liver injury, a less severe group of patients who have
coagulopathy but do not reach the threshold of encephalopathy.

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the
efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified
(IGIV-C) as a corticosteroid (CS)-sparing agent in subjects with CS-dependent Myasthenia
Gravis (MG).

The purpose of this study is to evaluate the safety and pharmacokinetics ASG-22CE as well as
assess the immunogenicity and antitumor activity in subjects with metastatic urothelial
cancer and other malignant solid tumors.